does glp 1 cause increased heart rate Direct cardiovascular effects of glucagon like peptide-1 | Diabetology & Metabolic Syndrome Mechanisms of GLP-1 Receptor Agonists

Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial

More importantly, the hazard ratio for major adverse cardiovascular events (including cardiovascular death, myocardial infarction, stroke, or hospitalization for unstable angina) for the pooled tirzepatide groups versus glargine was 0.74 (95% CI 0.511.08), suggesting no increased cardiovascular risk with tirzepatide compared to insulin glargine

Whether you're exploring GLP-1 weight loss medication or other approaches to metabolic health, you deserve care that's personalized, supportive, and focused on your overall wellbeing

This initiative aligns with broader efforts to integrate AI into healthcare operations

& Aronne, L